Mersana Therapeutics, Inc. financial data

Symbol
MRSN on Nasdaq
Industry
Pharmaceutical Preparations
Location
840 Memorial Drive, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 332 % -6.19%
Debt-to-equity 590 % +116%
Return On Equity -334 % -30.5%
Return On Assets -48.4 % +29.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 123M shares +1.8%
Common Stock, Shares, Outstanding 123M shares +1.84%
Entity Public Float 364M USD -9.79%
Common Stock, Value, Issued 12K USD 0%
Weighted Average Number of Shares Outstanding, Basic 122M shares +5.91%
Weighted Average Number of Shares Outstanding, Diluted 122M shares +5.91%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 29.9M USD -22.7%
Research and Development Expense 88M USD -54.3%
General and Administrative Expense 45.1M USD -31.6%
Nonoperating Income (Expense) 7.05M USD +54.5%
Net Income (Loss) Attributable to Parent -105M USD +51.3%
Earnings Per Share, Basic -0.85 USD/shares +58.1%
Earnings Per Share, Diluted -0.85 USD/shares +58.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59M USD -54.2%
Accounts Receivable, after Allowance for Credit Loss, Current 1.57M USD
Assets, Current 169M USD -43.1%
Property, Plant and Equipment, Net 3.83M USD -3.86%
Operating Lease, Right-of-Use Asset 6.18M USD -32.3%
Other Assets, Noncurrent 978K USD +89.2%
Assets 179M USD -42.4%
Accounts Payable, Current 3.01M USD -82.2%
Employee-related Liabilities, Current 7.81M USD +2.89%
Accrued Liabilities, Current 17.8M USD -46.9%
Contract with Customer, Liability, Current 29.3M USD +43.1%
Liabilities, Current 62.2M USD -17%
Contract with Customer, Liability, Noncurrent 87.6M USD -23.3%
Operating Lease, Liability, Noncurrent 3.27M USD -52.8%
Other Liabilities, Noncurrent 626K USD +724%
Liabilities 171M USD -22.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -71K USD -44.9%
Retained Earnings (Accumulated Deficit) -870M USD -13.7%
Stockholders' Equity Attributable to Parent 8.43M USD -90.6%
Liabilities and Equity 179M USD -42.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.7M USD -12.6%
Net Cash Provided by (Used in) Financing Activities 5.83M USD -73%
Net Cash Provided by (Used in) Investing Activities -72.5M USD -5297%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 123M shares +1.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -99.4M USD -1540%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.5M USD -54%
Interest Paid, Excluding Capitalized Interest, Operating Activities 871K USD +10.1%
Deferred Tax Assets, Valuation Allowance 239M USD +25.6%
Deferred Tax Assets, Gross 242M USD +24.9%
Operating Lease, Liability 8.4M USD -26.1%
Payments to Acquire Property, Plant, and Equipment 132K USD -85.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD +51.3%
Lessee, Operating Lease, Liability, to be Paid 9.47M USD -29.8%
Operating Lease, Liability, Current 3.65M USD +20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.19M USD +0.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.98M USD +3.06%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.07M USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.31M USD -68.7%
Deferred Tax Assets, Operating Loss Carryforwards 127M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.31M USD -68.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 423K USD +32.6%
Deferred Tax Assets, Net of Valuation Allowance 2.08M USD -27%
Share-based Payment Arrangement, Expense 17.2M USD -27.7%
Interest Expense 4.09M USD +14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%